The opinion of the court was delivered by: Magistrate Judge Geraldine Soat Brown
Judge Robert W. Gettleman
MEMORANDUM OPINION AND ORDER
Geraldine Soat Brown, United States Magistrate Judge
For the reasons discussed below, Plaintiff's Motion to Bar Supplementation of Rule 26(a)(2)(B) Disclosures of Dr. Michael Greenberg, Dr. James Wedner, and Joel Cohen (Pl.'s Mot. Bar) [dkt 226] is denied. Plaintiff's Motion In Limine No. 1 to Bar Testimony of Dr. Michael Greenberg, Dr. James Wedner, and Joel Cohen, or Any Other Opinion Witness, Regarding Use of Electronic Cigarettes by Plaintiff (Pl.'s MIL No. 1) [dkt 238]is denied without prejudice.
Plaintiff Steven Noffsinger alleges that while hauling Dynaprime in February 2007, he was exposed to Dynaprime fumes when a defective drum leaked, and consequently has suffered respiratory problems. (Pl.'s Am. Compl.) [Dkt 49.] Dynaprime is a solvent-based coating made by defendant Valspar Corporation. (Id. ¶ 1.)*fn1 Valspar's expert witnesses believe that Noffsinger's respiratory ailments are not caused by Dynaprime but are caused instead by Noffsinger's history of smoking. (Pl.'s Mot. Bar ¶ 8.)
At his October 8, 2009 deposition, Noffsinger was asked, "When was the last time you smoked a cigarette?" (Defs.' Resp. Bar, Ex. D, Dep. of Steven Noffsinger at 48.) [Dkt 234.] Noffsinger responded "May of 2007." (Id.) In May 2010, Valspar disclosed Dr. Michael Greenberg, Dr. James Wedner, and Mr. Joel Cohen as expert witnesses and served their reports pursuant to Fed. R. Civ. P. 26(a)(2)(B). (Defs.' Resp. MIL No. 1 at 4.) [Dkt 342.] Discovery closed on March 31, 2011 [dkt 139], and on June 30, 2011, Valspar moved for summary judgment [dkt 177, 178]. Valspar's motion was denied on March 15, 2012. (Mem. Op. and Order, Mar. 15, 2012.) [Dkt 217.]
On April 18, 2012, discovery was reopened to July 31, 2012 so that Valspar could determine Noffsinger's current condition. [See Dkt 220.] At his May 21, 2012 deposition, Noffsinger was again asked, "When did you last smoke cigarettes?" (Defs.' Resp. Bar, Ex. B, Dep. of Steven Noffsinger at 72.) This time he responded, "Real cigarettes or electronic cigarettes?" (Id.) He testified that in addition to occasionally having a real cigarette, he had been using electronic cigarettes since May 2007.*fn2 (Id. at 72, 78.) He did not believe that he had informed his physicians of his use of either real or electronic cigarettes. (Id. at 76, 78, 83.) On June 12, 2012, Noffsinger's physician Dr. James Tita verified that he was unaware that Noffsinger had been using electronic cigarettes. (Defs.' Resp. Bar, Ex. C, Dep. of Dr. James Tita at 42.)
On July 27, 2012, Valspar informed Noffsinger that it had provided its experts with Noffsinger's testimony, and that its experts would be providing supplemental reports reflecting that new testimony in the next 30 days. (Pl.'s Mot. Bar, Ex. E.) That resulted in a flurry of motions by Noffsinger. On July 30, 2012, Noffsinger filed a motion to bar the proposed supplementation. [Dkt 226.] Valspar responded, indicating that any supplementation will be limited to Noffsinger's testimony about his smoking, including his use of e-cigarettes. (Defs.' Resp. Bar at 5.) Noffsinger replied [dkt 236], and also filed a motion in limine to bar Valspar's experts from testifying regarding the use of electronic cigarettes [dkt 238], to which Valspar has responded. On September 12, 2012, Noffsinger filed a motion to submit additional evidence in support of his motion to bar supplementation. (Pl.'s Mot. Submit) [Dkt 283.] To that motion, Noffsinger attached invoices that show that Valspar's expert Joel Cohen performed research about e-cigarettes on June 4, 2012, and had prepared a draft supplementary report by August 23. (Id., Ex. A.) The motion to submit additional evidence was granted and Valspar was given an opportunity to respond, which it did. [Dkt 288, 338].
The parties had previously been ordered to submit a proposed pretrial order by September 6, 2012 [dkt 231], and the amended final proposed pretrial order was filed on September 11, 2012 [dkt 281]. In the proposed order, the parties noted that Valspar advised Noffsinger that it intends to supplement its expert disclosures, and that Noffsinger objects. (Id. ¶ 2(i)). According to Valspar, it has not yet supplemented its expert reports because it is "awaiting the ruling[s]" on Noffsinger's motions. (Defs.' Resp. MIL No. 1 at 5.) There is currently no trial date set.
The purpose of an expert report is to give "adequate notice of the substance of the expert's forthcoming testimony and to give the opposing party time to prepare for a response." Meyers v. Nat'l R.R. Passenger Corp., 619 F.3d 729, 734 (7th Cir. 2010). Among other things, an expert report must contain "a complete statement of all opinions the witness will express and the basis and reasons for them." Fed. R. Civ. P. 26(a)(2)(B)(i). Additionally, a party must "supplement or correct its disclosure . . . if the party learns that in some material respect the disclosure . . . is incomplete or incorrect, and if the additional or corrective information has not otherwise been made known to the other parties during the discovery process or in writing." Fed. R. Civ. P. 26(e)(1). For an expert who has provided a report under Rule 26(a)(2)(B), as Valspar's experts did, the duty to supplement extends to both information included in the report and to information given in the expert's deposition. Fed. R. Civ. P. 26(e)(2). Supplementation must be done by the time pretrial disclosures are due. Id. Pretrial disclosures must be served at least 30 days before trial, or as ordered by the court. Fed. R. Civ. P. 26(a)(3)(B).
If a party fails to disclose supplemental information required by Rule 26(e), the party is not allowed to use that information at trial unless the failure to disclose was substantially justified or harmless. Fed. R. Civ. P. 37(c)(1).
Noffsinger makes three arguments why Valspar's experts should not be allowed to supplement their reports or testify at trial regarding Noffsinger's use of electronic cigarettes: (1) Valspar has not requested leave of court to supplement its experts' reports; (2) Valspar purposely delayed supplementation until the end of the supplemental discovery period; and (3) any supplementation under Rule 26(e) is improper because Noffsinger's testimony only bolsters Valspar's experts' opinions and does ...